پیوندهای مفید
آمار
| تعداد نشریات | 20 |
| تعداد شماره‌ها | 1,093 |
| تعداد مقالات | 10,030 |
| تعداد مشاهده مقاله | 27,414,862 |
| تعداد دریافت فایل اصل مقاله | 7,568,699 |
The Utility of Serum HE4 in Predicting Myometrial Invasion in Patients with Endometrial Cancer | ||
| Middle East Journal of Cancer | ||
| مقاله 7، دوره 11، شماره 4 - شماره پیاپی 44، دی 2020، صفحه 438-444 اصل مقاله (1.08 M) | ||
| نوع مقاله: Original Article(s) | ||
| شناسه دیجیتال (DOI): 10.30476/mejc.2020.81579.1029 | ||
| نویسندگان | ||
| Malihe Hasanzadeh؛ Khatereh Vatanpour؛ Leila Pourali* | ||
| Department of Obstetrics and Gynecology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| چکیده | ||
| Background: Human epididymis protein 4 (HE4) is a novel tumor marker that has shown a strong potential in diagnosing and predicting the prognosis of endometrial cancer. In this study, we aimed to assess the association of tumor size and stage, ovarian involvement, lymph node metastasis, lymphovascular space invasion and deep myometrial invasion with preoperative serum levels of HE4 in endometrial cancer patients. Method: This cross-sectional study included patients with endometrial cancer awaiting surgery in Ghaem Hospital, Mashhad, Iran, from May 2016 to May 2017. We measured the HE4 levels preoperatively and gathered other required information postoperatively; collected data were analyzed using SPSS version 16. Results: We enrolled 104 endometrial cancer patients. Mean serum HE4 was 149.6±186.2pmol/l. Level of serum HE4 had significant positive correlations with tumor size and stage, lymph node metastasis, ovary involvement, lymphovascular space invasion and profound myometrial invasion (p <0.001). There was no association between age and myometrial invasion. Moreover, using ROC curve, we calculated a serum HE4 cut-off of 104 pmol/l to be 91% sensitive and 89.6% specific for the detection of deep myometrial invasion. Conclusion: HE4 is a novel biomarker capable of preoperatively predicting the depth of myometrial invasion with high specificity and sensitivity. This marker can be utilized in guiding the surgical plan of patients with endometrial cancer. | ||
| کلیدواژه‌ها | ||
| Endometrial cancer؛ HE4؛ Myometrial invasion؛ Lymphadenectomy؛ Surgical staging | ||
| اصل مقاله | ||
|
How to cite this article: Hasanzadeh M, Vatanpour KH, Pourali L. The utility of serum HE4 in predicting myometrial invasion in patients with endometrial cancer. Middle East J Cancer. 2020;11(4): 438-44. doi: 10.3 0476/mejc.2020.81579.1029. | ||
| مراجع | ||
|
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi: 10.3322/caac.21262. 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi: 10.3322/caac.21442. 3. Aalders JG, Thomas G. Endometrial cancer--revisiting the importance of pelvic and para aortic lymph nodes. Gynecol Oncol. 2007;104(1):222-31. 4. Loeb S, Partin AW, Schaeffer EM. Complications of pelvic lymphadenectomy: do the risks outweigh the benefits? Rev Urol. 2010;12(1):20-4. 5. Mohan DS, Samuels MA, Selim MA, Shalodi AD, Ellis RJ, Samuels JR, et al. Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma. Gynecol Oncol. 1998;70(2):165-71. 6. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2010;(1):CD007585. doi: 10.1002/14651858.CD007585.pub2. 7. Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol. 1998;71(3):340-3. 8. Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000;95(5):692-6. 9. Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol. 2004;95(3):546-51. 10. Manfredi R, Mirk P, Maresca G, Margariti PA, Testa A, Zannoni GF, et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology. 2004;231(2):372-8. 11. Moore R, Brown A, Miller C, Badgwell D, Lu Z, Verch T, et al. Utility of a novel serum tumor biomarker HE4 in patients with uterine cancer. Gynecol Oncol. 2008;110(2):196-201. doi: 10.1016/j.ygyno.2008.04.002. 12. Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer. 2011;21(7):1185-90. doi: 10.1097/IGC.0b013e3182229ad8. 13. Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol. 2013;34(1):571-6. doi: 10.1007/s13277-012-0583-0. 14. Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol. 2012;124(2):270-5. doi: 10.1016/j.ygyno.2011.10.025. 15. Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer. 2011;104(9):1418-25. doi: 10.1038/bjc.2011.109. 16. Frederick PJ, Straughn Jr JM. The role of comprehensive surgical staging in patients with endometrial cancer. Cancer Control. 2009;16(1):23-9. 17. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45(2):350-7. 18. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100(8):1315-9. doi: 10.1038/sj.bjc.6605011. 19. Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011;32(6):1087-95. doi: 10.1007/s13277-011-0204-3. 20. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012;206(4):351.e1-8. doi: 10.1016/j.ajog.2011.12.029. 21. Brennan DJ, Hackethal A, Metcalf AM, Coward J, Ferguson K, Oehler MK, et al. Serum HE4 as a prognostic marker in endometrial cancer—a population based study. Gynecol Oncol. 2014;132(1):159-65. doi: 10.1016/j.ygyno.2013.10.036. 22. Antonsen SL, Høgdall E, Christensen IJ, Lydolph M, Tabor A, Loft Jakobsen A, et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand. 2013;92(11):1313-22. doi: 10.1111/aogs.12235. 23. Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol. 2012;126(2):186-91. doi: 10.1016/j.ygyno.2012.04.022. | ||
|
آمار تعداد مشاهده مقاله: 5,421 تعداد دریافت فایل اصل مقاله: 5,190 |
||